Davis Polk advised the sole book-running manager on an SEC-registered offering by Celgene Corporation of $500 million aggregate principal amount of 2.250% senior notes due 2021. Celgene intends to use the net proceeds from the offering for general corporate purposes.

Headquartered in Summit, New Jersey, Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory-related diseases.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Donald Shum and Mahfouz Basith. Partner Frank J. Azzopardi and associates Bonnie Chen and Carrie Guo provided intellectual property and technology advice. Partner Neil Barr and associate Joshua J. Micelotta provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post